Biological angstrom hole system based on small-conductivity mechanical force sensitive channel

Through the Emmepore system based on small conductivity mechanical force sensitive channels, the problems of high genetic detection cost and insufficient sensitivity in nanopore detection technology are solved, and efficient detection of multiple molecules is achieved, with good specificity and sensitivity.

CN119061104APending Publication Date: 2024-12-03SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411186556.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-08-30
Filing Date
2022-06-29
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing nanopore detection technology has problems such as high cost, insufficient sensitivity and accuracy in genetic testing, and the channel structure regulation of protein nanopores is poor, making it difficult to adapt to molecular detection of multiple sizes.

Method used

Develop an Emmehole system based on small conductivity mechanical force sensitivity channels. Using the mechanical force sensitivity characteristics of MscS Emmehole, adjust the aperture through mechanical stimulation and physical state changes, and realize efficient detection of charged molecules, which is suitable for a variety of Molecules of type and size.

Benefits of technology

It realizes low-cost and high-common gene detection and DNA calculation, can directly detect nucleotides, amino acids, drug molecules, etc., has good specificity and sensitivity, and is suitable for the analysis of complex samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061104A_ABST
    Figure CN119061104A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of nanopore detection, and particularly relates to a biological angstrom pore system based on a small conductivity mechanical force sensitive channel (MscS). The invention provides an application of an angstrom pore system in detection of charged molecules, and is characterized in that the angstrom pore system comprises an MscS angstrom pore, an insulating film, a first medium and a second medium. Reversible in-situ adjustment of the aperture of the MscS angstrom pore can be realized only by changing external conditions, and the MscS angstrom pore is suitable for direct detection of molecules of various types and sizes, such as nucleotides, amino acids, peptides, drug molecules and the like.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application based on the Chinese invention patent application with application number 202210758241.7, application date June 29, 2022, and invention name “Biological angstrom pore system based on small conductance mechanical force-sensitive channel”.

[0002] This application claims the priority of the Chinese invention patent application [CN2021110062606] filed on August 30, 2021, entitled “Biological nanopore system for dNTPs and new coronavirus detection based on PaMscS”, and the priority of the Chinese invention patent application [CN2021110042496] filed on August 30, 2021, entitled “Biological nanopore system for small molecule drug detection and whole blood detection based on PaMscS”. The two priority invention patent applications are incorporated by reference in their entirety. Technical Field

[0003] The invention belongs to the field of nanopore detection, and in particular relates to a biological angstrom pore system based on a small-conductance mechanical force sensitive channel. Background Art

[0004] Nanopore single-molecule detection technology is a sensor detection technology that combines the advantages of simple operation, high sensitivity, fast detection speed, and no labeling. It is widely used in protein detection, gene sequencing, and marker detection. At present, the cost, sensitivity, and accuracy of gene detection are the main problems that need to be solved in the development of this detection technology. Therefore, the development of new nanopore materials is a key means to solve these problems.

[0005] A biological nanopore is a naturally formed nanoscale pore whose pore size is similar to the size of many important biological molecules. When a molecule passes through the channel inside the nanopore, a specific blockade current and translocation event are generated. According to the blockade current and translocation frequency of the molecule, qualitative and quantitative analysis of the target molecule can be achieved. Therefore, the channel pore size is the dominant factor affecting the detection ability and application range of the nanopore. Some protein nanopores with suitable channel pore sizes have been used for nanobiotechnology applications, such as α-hemolysin (α-HL), MspA, CsgG, Aerolysin, phi29 connector, etc. These biological nanopores are mainly derived from bacterial porins or viral phyla and have pore sizes (1.0nm-3.6nm) of the order of single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA). Therefore, they are suitable for detecting nucleic acids and have been used for DNA / RNA sequencing, nucleic acid biomarker detection and biomolecular interaction research. However, currently, biological nanopores need to be locally modified according to specific application requirements, such as site-directed mutagenesis or modification of specific aptamers, in order to adapt to a wider range of sequencing. Taking α-HL as an example, its limited pore size is about 1.4nm, so its application range is limited to the analysis of ssDNA, RNA or other molecules. By modifying it with cyclodextrin, it can be used to directly detect monophosphate deoxyribonucleoside dNMPs without fluorescent labeling. However, changing the pore size of biological nanopores by modification requires a lot of bioengineering technology assistance. In addition, compared with solid-state nanopores, protein pores are much less flexible in adjusting size. In this sense, there is an urgent need to find a nanopore with a flexible structure to efficiently detect molecules of various sizes.

[0006] In summary, in order to improve the deficiencies of the prior art, the present invention provides a novel biological angstrom pore system based on a small conductance mechanical force sensitive channel. The angstrom pore is a pore protein with a smaller size than a nanopore. This novel protein angstrom pore system does not require an adapter or modification, and provides a low-cost, highly versatile new approach for real-time molecular sensing, gene detection and DNA computing. Summary of the invention

[0007] In view of this, the present invention provides an application of an angstrom pore system in detecting charged molecules, characterized in that the angstrom pore system comprises an angstrom pore, an insulating membrane, a first medium and a second medium; the angstrom pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the angstrom pore provides a channel connecting the first medium and the second medium, and after a driving force is applied between the first medium and the second medium, the charged molecules located in the first medium interact with the angstrom pore; the angstrom pore is an MscS angstrom pore, and the angstrom pore has a radially symmetrical and cylindrical heptamer structure, and the heptamer structure comprises 7 side openings and 1 bottom opening.

[0008] Furthermore, the charge properties and / or aperture sizes of the openings are adjustable.

[0009] Furthermore, the opening is adjusted in a manner including subjecting the insulating film to mechanical force stimulation and / or changing the physical state of the insulating film.

[0010] Furthermore, the mechanical force stimulation includes one or more of the following: changes in the osmotic pressure difference of the medium on both sides of the insulating film, direct physical stimulation of the insulating film by microneedles, and stimulation of the insulating film by negative air pressure. The changes in the physical state of the insulating film include changes in the thickness of the insulating film, changes in the composition of the insulating film, changes in the surface curvature of the insulating film, etc.

[0011] Furthermore, the aperture of the opening can be adjusted according to the following methods: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.

[0012] Furthermore, the angstrom is derived from Bacillus.

[0013] Furthermore, the angstrom is derived from one or more of Pseudomonas aeruginosa, Escherichia coli, Thermoanaerobic Bacteria of Tengchong and Helicobacter pylori.

[0014] Furthermore, the angstrom pore is a MscS variant.

[0015] Furthermore, the MscS variants include side pore volume variants and / or side pore charge variants.

[0016] Furthermore, the insulating film includes a phospholipid membrane and / or a polymer membrane.

[0017] Furthermore, the charged molecules include one or more of nucleotides, amino acids, peptides, and drug molecules.

[0018] Furthermore, the angstrom pore is a PaMscS variant.

[0019] Further, the angstrom pores include one or more of the following variants: 130A, 130H, 180R, 271I, 130S and 130P.

[0020] Further, the molar mass of the drug molecule is less than 1000 g / mol. Specifically, the drug molecule can be pyrophosphate, gentamicin sulfate, neomycin sulfate, sisomicin, glutamic acid, etc.

[0021] Furthermore, the first medium and / or the second medium includes one or more of a sodium chloride solution, a lithium chloride solution, a cesium chloride solution, a potassium chloride solution and a sodium bromide solution.

[0022] On the other hand, the present invention also provides a biological angstrom pore system, characterized in that the biological angstrom pore system includes an angstrom pore, an insulating membrane, a first medium and a second medium, the angstrom pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, and the angstrom pore provides a channel connecting the first medium and the second medium; the angstrom pore is an MscS variant angstrom pore, the angstrom pore has a radially symmetrical and cylindrical heptamer structure, and the heptamer structure includes 7 side openings and 1 bottom opening.

[0023] Furthermore, the angstrom pore is a side pore volume variant and / or a side pore charge variant of MscS.

[0024] Furthermore, the insulating membrane comprises a phospholipid membrane and / or a polymer membrane. The phospholipid membrane comprises DPHPC, DOPC, and E. coli lipid; and the polymer membrane comprises a triblock copolymer polymer membrane.

[0025] Furthermore, the angstrom is derived from Bacillus.

[0026] Furthermore, the angstrom is derived from one or more of Pseudomonas aeruginosa, Escherichia coli, Thermoanaerobic Bacteria of Tengchong and Helicobacter pylori.

[0027] Furthermore, the angstrom pore is a PaMscS variant.

[0028] Further, the angstrom pore includes one or more of the following variants: 130A, 130H, 180R, 271I, 130S and 130P. The mutation sites of the above variants are located at the side openings of the cytoplasmic end, specifically involving changes in the volume and charge properties of amino acids. Through mutation, the pore size (also understood as "pore size") of the mutated side pore can be changed, thereby improving the detection ability of molecules with a specific molecular volume; the local charge characteristics of the mutated side pore channel can also be changed, thereby improving the detection ability of specific charged molecules; and the stability of the protein channel current of the mutant PaMscS angstrom pore can also be enhanced.

[0029] Furthermore, the charge properties and / or aperture sizes of the openings are adjustable.

[0030] Furthermore, the opening is adjusted in a manner including subjecting the insulating film to mechanical force stimulation and / or changing the physical state of the insulating film.

[0031] Furthermore, the mechanical force stimulation includes one or more of a change in the osmotic pressure difference of the medium on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by a microneedle, and stimulation of the insulating membrane by negative air pressure.

[0032] Furthermore, the aperture of the opening can be adjusted according to the following methods: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.

[0033] On the other hand, the present invention also provides the use of the above-mentioned biological angstrom pore system in detecting charged molecules, characterized in that the charged molecules include one or more of nucleotides, amino acids, peptides, and drug molecules.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The present invention provides an application of an angstrom pore system in detecting charged molecules, wherein the angstrom pore system comprises an MscS angstrom pore. The present invention creatively forms an angstrom pore system with a mechanosensitive channel of small conductance (MscS), and utilizes the characteristics of the mechanosensitive channel protein to detect charged molecules, which is specifically embodied as follows:

[0036] 1) The pore size of the MscS angstrom pore is narrow. It is estimated that the pore size of the MscS angstrom pore ranges from 6 to 16 angstroms, which is much smaller than the nanopores commonly used in the prior art (for example, the pore size of the α-hemolysin nanopore is about 1.4-2.4 nm, i.e., 14–24 angstroms).

[0037] 2) The pore size of the MscS angstrom pore is adjustable (it can also be understood as a flexible structure). The MscS angstrom pore can convert mechanical stimulation into electrical signals or biochemical signals within milliseconds, thereby inducing the regulation of the channel configuration. By utilizing the sensitivity of the MscS angstrom pore to the mechanical force stimulation and / or the change in the physical state of the insulating membrane, the pore size of the MscS angstrom pore can be adjusted by affecting the insulating membrane without complicated chemical modification. For example, the concentration of the first medium and the second medium (i.e., 30mM NaCl / 300mM NaCl, 100mM NaCl / 300mM NaCl and 300mM NaCl / 300mM NaCl) can be adjusted to adjust the osmotic pressure difference on both sides of the insulating membrane and then adjust the pore size, thereby optimizing the selectivity for dNTPs and improving the discrimination of dNTPs. Protein nanopores in the prior art usually have a fixed channel structure, and additional protein engineering modification or chemical modification is required to achieve channel structure adjustment. The pore size of the MscS angstrom pore provided by the present invention can be reversibly adjusted in situ simply by changing the external conditions, and is suitable for direct detection of molecules of various types and sizes.

[0038] 3) The angstrom pore system provided by the present invention can be applied to single-molecule sensing and detection. The angstrom pore system provided by the present invention is suitable for a variety of charged molecules (theoretically, as long as the size is smaller than the pore size of the MscS angstrom pore, the molecule can be sensed and detected), such as nucleotides, amino acids, peptides, drug molecules, etc.; while larger-sized nucleic acids (such as ssDNA) and proteins (such as proteins in whole blood samples) cannot enter the channel of the MscS angstrom pore and will not interfere with the detection molecules.

[0039] 4) Based on the above characteristics, the application scenarios of the angstrom system provided by the present invention are broad. For example, mutations can be introduced into the side holes of the MscS angstrom pore to adjust the volume (e.g., replacing W with A, S, P) and charge (e.g., replacing W with H, replacing K with R) of the amino acids at the side holes to achieve better detection of specific charged molecules and molecules of specific sizes. For example, the angstrom system provided by the present invention can directly detect single nucleotides, or it can be used with a consumption strategy (e.g., detecting the remaining nucleotides of the nucleic acid amplification system) to identify the presence or absence of target nucleic acids in the sample, such as in the diagnosis of SARS-CoV-2 samples, showing good specificity and sensitivity. For example, the angstrom system provided by the present invention can detect the presence or absence of drug molecules in complex samples (e.g., whole blood), and can also directly measure the drug concentration in whole blood with molar sensitivity and continuous, real-time monitoring of blood drug concentrations in living animals, showing robustness and sensitivity. For example, the angstrom system provided by the present invention can also detect amino acids and short peptides (e.g., dipeptides).

[0040] As used herein, the term "derived from" refers not only to proteins produced by the strain of the organism in question, but also to proteins encoded by a DNA sequence isolated from such strain and produced in a host organism containing such DNA sequence.

[0041] As used herein, the term "charged molecule" refers to a substance with a net charge and a size less than or equal to the pore size of the angstrom pore involved in the present invention. Exemplary charged molecules include nucleotides, amino acids, peptides, drug molecules and / or other charged small molecules (e.g., short peptides). BRIEF DESCRIPTION OF THE DRAWINGS

[0042] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art descriptions. Obviously, the drawings described below are some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor.

[0043] Figure 1 Electrophysiological testing and dNTP detection based on PaMscS angstrom pores are shown;

[0044] Figure 2 The transport frequency of dNTPs through the PaMscS1 pore under different osmotic pressure differences is shown;

[0045] Figure 3 SARS-CoV-2 nucleic acid detection based on real-time monitoring of dNTPs consumption by PaMscS2 is shown;

[0046] Figure 4 Detection of AFP aptamer and miR21 by dNTPs consumption by PaMscS1 is shown;

[0047] Figure 5 The SDS-PAGE results of PaMscS protein (1: wild-type PaMscS; 2: W130A mutant; 3: K180R mutant; 4: marker) are shown;

[0048] Figure 6 The current signal or current distribution of wild-type or mutant PaMscS is shown;

[0049] Figure 7 shows the current trace through a single PaMscS1 angstrom pore under a ramp voltage from 0 mV to +100 mV;

[0050] Figure 8 The transport capacity of different ions through the PaMscS1 pore is shown;

[0051] Fig. 9 The translocation frequency statistics of dNTPs through the PaMscS1 angstrom pore at different voltages are shown (n=3);

[0052] Fig.10 The current trace and dwell time distribution of single nucleotide detection by PaMscS1 are shown;

[0053] Fig.11 It was shown that single-stranded DNA cannot translocate through the PaMscS1 pore;

[0054] Fig.12 The results of angstrom pore detection of SARS-CoV-2orf1ab gene by loop-mediated isothermal amplification (LAMP) are shown;

[0055] Fig.13 The results of native PAGE electrophoresis of PCR reagents mixed with miR21 and AFP aptamers are shown;

[0056] Fig.14 Shown is a drug single-molecule biosensing experiment based on PaMscS3(V271I) angstrom pore;

[0057] Fig.15 Drug concentration measurements of whole blood samples are shown;

[0058] Fig.16 A proof-of-concept experiment for continuous monitoring of drug concentrations in living rats via angstrom pores is shown;

[0059] Fig.17 Continuous current traces of the PaMscS3(V271I) angstrom pores of gentamicin sulfate are shown;

[0060] Fig.18 Continuous current traces of the PaMscS3(V271I) angstrom pore with neomycin sulfate are shown;

[0061] Fig.19 It was shown that high concentrations of gentamicin sulfate and neomycin sulfate can block the PaMscS3(V271I) angstrom pores for a long time;

[0062] Fig. 20 It was shown that the MspA-2NNN angstrom pores could be frequently blocked by whole blood samples (10 μL whole blood sample was added to the 1 mL end);

[0063] Fig.21 shows the continuous current trace of PaMscS3(V271I) angstrom pore in blood sample;

[0064] Fig. 22shows the current trace of a rat whole blood sample directly measured through the PaMscS3(V271I) angstrom pore;

[0065] Fig.23 The current signal of gentamicin sulfate passing through the angstrom pore of PaMscS3 (V271I) from -50 mV to -80 mV is shown;

[0066] Fig.24 The current signal of sisomicin passing through the angstrom pore of PaMscS3(V271I) from -50 mV to -80 mV is shown;

[0067] Fig.25 Single channel embedded current traces of wild-type EcMscS are shown (voltage +100 mV, conductance solution 30 mM:300 mM NaCl);

[0068] Fig.26 Channel scanning voltage (−100 mV to 100 mV) of wild-type EcMscS is shown;

[0069] Fig. 27 The conductance distribution of wild-type EcMscS is shown;

[0070] Fig.28 The sequence alignment of PaMscS with MscS of other bacteria is shown;

[0071] Fig.29 dNTP detection based on wild-type PaMscS angstrom pore is shown;

[0072] Fig.30 The current trace of glutamate detection by PaMscS1 is shown;

[0073] Fig.31 The amino acid detection scheme based on PaMscS angstrom pore and the blockade current distribution of different amino acids are shown. DETAILED DESCRIPTION

[0074] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0075] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.

[0076] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.

[0077] In this specification, certain embodiments may be disclosed in a format of being in a certain range. It should be understood that such description of "being in a certain range" is merely for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values ​​within this range. For example, the description of the range 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within this range, such as 1, 2, 3, 4, 5 and 6. Regardless of the breadth of the range, the above rules apply.

[0078] Detailed description of the drawings

[0079] Figure 1 : A. Schematic diagram of the electrophysiological measurement chamber. B. Single-hole insertion of PaMscS1 and PaMscS2 angstrom pores at a voltage of +50 mv. C. IV relationship of PaMscS1 and PaMscS2 angstrom pores in the voltage range of -50 mv to +50 mv. D. Conductance distribution of PaMscS1 and PaMscS2 angstrom pores (N=18, respectively) (buffer conditions are -cis end: 300 mM NaCl, -trans end: 30 mM NaCl). E. Detection of dNTPs through PaMscS mutant angstrom pores (buffer conditions are -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, and voltage is +50 mv).

[0080] Figure 2: The translocation frequencies of dCTP (in orange) and dGTP (in blue) were tested under different osmotic pressure difference conditions, symmetric (A, 300mM NaCl: 300mM NaCl for cis end: trans end), low osmotic pressure difference (LOD) (B, 300mM NaCl: 100mM NaCl for cis end: trans end), and high osmotic pressure difference (HOD) (C, 300mM NaCl: 30mM NaCl for cis end: trans end). Four groups of dNTPs concentrations, 0.5mM, 1.0mM, 1.5mM, and 2.0mM, were used to test the translocation of dCTP and dGTP. D. The relationship between the translocation frequency and the dCTP / dGTP concentration under symmetric, low osmotic pressure difference, and high osmotic pressure difference conditions (n=3 for each data point). E. Under 3 different osmotic pressure difference conditions, f dCTP and f dGTP rate of increase.

[0081] Figure 3 :A. Schematic diagram of angstrom pore detection of SARS-CoV-2. B. Detection results of SARS-CoV-2 Orf1ab gene under gradient copy number (buffer conditions: -cis end: 300mM NaCl, -trans end: 100mM NaCl, voltage +50mV, negative control (NC) group: n=4, 10^11 copies / mL group: n=4, 10^8 copies / mL group: n=4, 10^5 copies / mL group: n=4, 10^3 copies / mL group: n=3). C. Test results of 22 clinical samples, including 15 positive samples (patient numbers: 1-15) and 7 negative samples (patient numbers: 16-22), 21 samples of angstrom test results were consistent with the hospital qPCR test results (patient numbers: 1-15, 17-22), and 1 negative sample (patient number: 16) was diagnosed as positive by angstrom (buffer conditions: -cis end: 300mM NaCl, -trans end: 100mM NaCl, voltage is +50mV). D. Monitoring the consumption of dNTPs by MscS angstrom can be combined with nucleic acid amplification techniques (NAAT), such as polymerase chain reaction (PCR) and chain displacement amplification (SDA).

[0082] Figure 4:A. Schematic diagram of the detection strategy. B. Current traces of the no-target control group, miR21 group, AFP aptamer group, and group with both miR21 and AFP aptamer. C. Current distribution of the four detection groups. D. Relative increase of dATP and dGTP signals in the four groups. Samples without miR21 and AFP aptamer will not lead to dNTPs consumption; samples with miR21 will lead to more dATP consumption and relatively lower dATP translocation frequency; samples with AFP aptamer will lead to more dGTP consumption and relatively lower dGTP translocation frequency; samples with both miR21 and AFP aptamer will lead to more dATP and dGTP consumption and relatively lower dATP and dGTP translocation frequency (buffer conditions are -cis end: 300mM NaCl, -trans end: 100mM NaCl, voltage is +50mV, n=3 for each experiment).

[0083] Figure 6 :A. Background signal frequency of wild-type PaMscS and mutant PaMscS1 and PaMscS2. The background noise frequency of PaMscS1 and PaMscS2 is lower than that of wild-type PaMscS (voltage is +50mv, n≥3). B. Time of insertion of PaMscS1 and PaMscS2 angstrom pores. PaMscS2 angstrom pores have higher membrane fusion efficiency than PaMscS1 (n≥3). C. dNTPs blocking current distribution of PaMscS1 and PaMscS2 angstrom pores.

[0084] Figure 7 : Current trace through a single PaMscS1 angstrom pore under a ramp voltage from 0 mV to +100 mV: Voltage gating was observed when the voltage was increased above +90 mV (buffer conditions were -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, sampling frequency: 4999 Hz).

[0085] Figure 8 : Buffer conditions were: 300 mM NaCl on the -cis side, 30 mM NaCl on the -trans side, n ≥ 3 for each data point, mean ± SD.

[0086] Fig.10 : Dwell time distribution: dGTP (A), dATP (B), dTTP (C) and dCTP (D); the concentration of each nucleotide was 2 mM and the buffer conditions were -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, voltage was +50 mV.

[0087] Fig.11: Voltage: +50 mV; Buffer conditions: 300 mM NaCl on the cis side, 30 mM NaCl on the trans side. The final concentration of ssDNA was 5 μM, and the sequence was 5′TAGCTTATCAGACTGATGTTGA 3′ (SEQ ID NO: 5).

[0088] Fig.12 : Samples containing 10^3 copies / mL to 10^11 copies / mL of the Orf1ab gene can be tested.

[0089] Fig.13 : 1. DNA template 1 (containing poly T); 2. DNA template 2 (containing poly C); 3. PCR reagents with miR21 and AFP adaptors; 4. Control group (without miR21 and AFP adaptors).

[0090] Fig.14 :A. Results of detecting gentamicin sulfate by PaMscS3 (V271I) angstrom pores, including representative current traces and blocking signals. B. Results of detecting neomycin sulfate by PaMscS3 angstrom pores. C. Quantitative standard curve of gentamicin sulfate (N=3) and heat map of blocking signals (right, 878 blocking events). D. Quantitative standard curve of neomycin sulfate (middle, N=4) and heat map of blocking signals (right, 883 blocking events). The electrolyte conditions were -cis end: 300mM NaCl, -trans end: 30mM NaCl, 10mM HEPES, pH 7.0, and the voltage for drug detection was -50mV. E. Comparison of the detection results of 1.5μM gentamicin sulfate between LC-MS and PaMscS3 angstrom pores. The electrolyte conditions were -cis end: 130 mM NaCl, -trans end: 130 mM NaCl, 10 mM HEPES, pH 7.0, and the detection voltage of the drug was -50 mV.

[0091] Fig.15:A. Whole blood samples were directly detected by PaMscS3 (V271I) angstrom pores. After adding whole blood samples, PaMscS3 angstrom pores remained open. The electrolyte conditions were -cis end: 130mM NaCl, -trans end: 130mM NaCl, 10mM HEPES, pH 7.0, and voltage of -50mV. B. After adding 20μL of rat blood, the conductivity buffer at the -cis end turned red. C. The percentage of channel openness of whole blood samples. D. The quantitative standard curve of gentamicin sulfate ranged from 0 to 3μM. E. The drug concentration of rats at different time intervals after injection of gentamicin was measured by PaMscS3 angstrom pores. The electrolyte conditions for whole blood angstrom pore detection were -cis end: 130mM NaCl, -trans end: 130mM NaCl, 10mM HEPES, pH 7.0, voltage of -50mV, N≥3.

[0092] Fig.16 :A. The apparatus of the drug concentration monitoring system for rats. B. The quantitative standard curve of gentamicin sulfate ranges from 0 to 30 μM. C. Typical current traces of PaMscS3 (V271I) angstrom pores during drug concentration monitoring with injection of 4 mg / kg and 20 mg / kg gentamicin sulfate. D. Continuous drug blood concentration monitoring results of rats through PaMscS3 angstrom pores with different doses of gentamicin sulfate (N=1). The gray data points indicate that the drug blocking signal frequency is higher than the highest signal frequency within the standard curve range, and double-step signals appear frequently and make quantification inaccurate. The electrolyte conditions are -cis end: 130 mM NaCl, -trans end: 130 mM NaCl, 10 mM HEPES, pH 7.0, and the voltage is -50 mV.

[0093] Fig.17 : Current traces of the angstrom pore background and after the addition of gentamicin sulfate. The electrolyte conditions were -cis end: 300 mM NaCl, -trans end: 30 mM NaCl, 10 mM HEPES, pH 7.0, voltage was -50 mV, N=3.

[0094] Fig.18 : Background current trace of angstrom pore and trace after adding neomycin sulfate. Electrolyte conditions are -cis end: 300mM NaCl, -trans end: 30mM NaCl, 10mM HEPES, pH 7.0, voltage is -50mV, N=3.

[0095] Fig.19: At high drug concentrations, the drug blocking signal is difficult to count and the PaMscS3(V271I) angstrom pore can be blocked for a long time, resulting in the inability to calculate quantitatively. The electrolyte conditions are -cis end: 300mM NaCl, -trans end: 30mM NaCl, 10mM HEPES, pH 7.0, and the voltage for drug detection is -50mV.

[0096] Fig. 20 : Electrolyte conditions were -cis end: 300 mM NaCl, -trans end: 300 mM NaCl, 10 mM HEPES, pH 7.0, voltage was +100 mV, N=3.

[0097] Fig.21 : Current traces of angstrom pore background and after addition of whole blood sample.

[0098] Fig. 22 : 20 μL of rat whole blood was added to the -cis end (1 mL), and the PaMscS3 (V271I) angstrom pore can work well in the presence of whole blood samples.

[0099] Fig.23 :The electrolyte conditions are -cis end: 130mM NaCl, -trans end: 130mM NaCl, 10mM HEPES, pH 7.0. It is worth noting that two peaks appeared in the gradient voltage.

[0100] Fig.24 :Electrolyte conditions are -cis end: 130mM NaCl, -trans end: 130mM NaCl, 10mM HEPES, pH7.0. The structure of sisomicin is close to the C1a component of gentamicin sulfate. Under gradient voltage, only one blocking current peak was observed.

[0101] Fig.28 : Sequence alignment of the MscS family. Fig.28 The residues highlighted in red in d are identical in the four sequences; the cylinders above the sequences are designated as α-helices and β-strands.

[0102] Emikoon

[0103] The angstrom used in the present invention is a small conductance mechanosensitive channel (Mechanosensitive channel of small conductance, MscS), preferably PaMscS (Pseudomonas aeruginosa small conductance mechanosensitive channel) or its variant. The variant (also understood as a "mutant") can be a naturally occurring variant expressed by an organism (e.g., Pseudomonas aeruginosa). Variants also include non-naturally occurring variants produced by recombinant technology. In the present invention, "PaMscS variant", "mutant PaMscS", "mutant PaMscS", "PaMscS mutant" have the same meaning unless otherwise indicated.

[0104] In one embodiment of the present invention, the angstrom pore may be an MscS variant. Amino acid substitutions may be made to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4, for example, single or multiple amino acid substitutions. The substitution may be a conservative substitution or a non-conservative substitution. Preferably, non-conservative substitutions may be made to one or more positions of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4, wherein the substituted amino acid residues are replaced by amino acids with significantly different chemical properties and / or physical sizes. Further, the MscS variants may be divided into side pore volume variants and side pore charge variants. Side pore volume variants refer to variants in which the mutation site is located at the side opening of the cytoplasmic end (also understood as a "side pore") and the side pore volume is changed by changing the amino acid at the site. Side pore charge variants refer to variants in which the mutation site is located at the side opening of the cytoplasmic end and the side pore charge is changed by changing the amino acid at the site. For example, the side pore volume variant may be a replacement of a larger amino acid (e.g., tryptophan (W)) with a smaller amino acid (e.g., alanine (A), serine (S) or proline (P)), or vice versa. Side pore charge variants may be a replacement of an amino acid with a certain charge with an oppositely charged or neutral amino acid, or a replacement of a neutral amino acid with a charged amino acid. In general, non-limiting examples of positively charged amino acids include histidine, arginine and lysine; non-limiting examples of negatively charged amino acids include aspartic acid and glutamic acid; non-limiting examples of neutral amino acids include glycine, alanine, phenylalanine, valine, leucine, isoleucine, cysteine, asparagine, glutamine, serine, threonine, tyrosine, methionine, proline and tryptophan. Conservative or non-conservative substitutions of amino acids, as well as many different types of modifications (deletions, substitutions, additions) of amino acids are well known in the art, and those skilled in the art can modify MscS according to actual conditions to obtain corresponding MscS variants. The modification means include modifying the corresponding DNA sequence (for example, directly synthesizing the corresponding protein after modifying the DNA sequence information or performing site-directed mutation on the DNA sequence using PCR) to obtain the corresponding variant (and its corresponding DNA sequence).

[0105] In a specific embodiment, the MscS variant can be a PaMscS variant. The PaMscS variant includes, for example, one or more of 130A, 130H, 180R, 271I, 130S and 130P. The side pore volume mutants of PaMscS include, for example, 130A, 130S, 130P, and the side pore charge variants of PaMscS include, for example, 130H, 180R, 271I. Such modification can change the pore size (also understood as "pore size") of the modified side pore, thereby improving the detection capability of analytes of a specific molecular volume; it can also change the local charge characteristics of the modified side pore channel, thereby improving the detection capability of specific charged analytes; it can also enhance the stability of the protein channel current of the PaMscS variant.

[0106] In one embodiment of the present invention, the angstrom pore may be a wild-type PaMscS, which has a high background noise but still has the ability to detect analytes.

[0107] In one embodiment of the present invention, the angstrom pore may be a wild-type EcMscS (small conductance mechanosensitive channel of Escherichia coli) or a variant thereof. The structures of EcMscS and PaMscS are highly similar, and they can also form a stable channel current and have the ability to detect analytes. The sequence similarity between PaMscS and EcMscS is 60%. Conservative or non-conservative substitutions of amino acids, as well as many different types of modifications (deletions, substitutions, additions) of amino acids are well known in the art, and those skilled in the art can modify EcMscS according to actual conditions to obtain corresponding EcMscS variants.

[0108] In another embodiment of the present invention, in addition to Escherichia coli and Pseudomonas aeruginosa, the angstrom can also be derived from other bacilli, such as Thermoanaerobacter tengcongensis and Helicobacter pylori. The structures of PaMscS, TtMscS and HpMscS are also highly similar, and the sequence similarities are 55% and 44%, respectively. Combining the actual electrophysiological detection results of PaMscS and EcMscS, it can be seen that the reason why MscS can be used as an angstrom detection analyte is its highly similar structure and similar function. Conservative substitution or non-conservative substitution of amino acids, as well as many different types of modifications (deletion, substitution, addition) of amino acids are well known in the art, and those skilled in the art can modify MscS according to actual conditions to obtain corresponding MscS variants.

[0109] Analytes

[0110] The analyte is a charged substance. If the analyte has a net charge, it is charged. The analyte can be negatively charged or positively charged. If the analyte has a net negative charge, it is negatively charged. If the analyte has a net positive charge, it is positively charged. Suitable analytes should be substances with a size less than or equal to the pore size of the angstrom pore, preferably nucleotides, amino acids, peptides, drug molecules.

[0111] In one embodiment of the present invention, the analyte can be a nucleotide. "Nucleotide" refers to a monomeric unit consisting of a heterocyclic base, a sugar and a phosphate group. It should be understood that the heterocyclic base includes naturally occurring bases (guanine (G), adenine (A), cytosine (C), thymine (T) and uracil (U)) and non-natural base analogs. Sugar includes naturally occurring sugars (deoxyribose and ribose) and non-natural sugar analogs. The nucleotide includes deoxyribonucleotides and ribonucleotides, such as ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP, GMP, UMP, TMP, CMP, dGMP, dAMP, dTMP, dCMP, dUMP, ADP, GDP, TDP, UDP, CDP, dADP, dGDP, dTDP, dUDP, dCDP. The nucleotide includes naturally occurring nucleotides and non-natural nucleotide analogs that hybridize with nucleic acids in a manner similar to naturally occurring nucleotides. The nucleotide is free (or can be understood as "single"). Preferably, the nucleotide is ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP.

[0112] In one embodiment of the invention, the analyte can be an amino acid. "Amino acid" refers to any of the 20 naturally occurring amino acids found in proteins, D-stereoisomers of naturally occurring amino acids (e.g., D-threonine), unnatural amino acids, and chemically modified amino acids. Each of these amino acid types is not mutually exclusive. The following abbreviations are used for the 20 naturally occurring amino acids: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V). The specific properties of amino acids (e.g., polarity, charge, hydrophilicity, average volume) are known to those skilled in the art. In another embodiment of the present invention, the analyte can be a short peptide, such as a dipeptide.

[0113] In one embodiment of the present invention, the analyte can be a drug molecule. A drug molecule can be a compound. More specifically, a "drug molecule" can be a drug with a molecular weight of 1000 g / mol or less (e.g., less than 800, 700, 600, 500, 400, 300 or 200 g / mol). Preferably, the drug molecule can be an aminoglycoside antibiotic. In another embodiment of the present invention, the drug molecule includes amino acids and salts thereof (including non-drugable amino acids) and peptides.

[0114] Angstrom pore system

[0115] The "Angstrom pore system" includes a pore with an Angstrom size (abbreviated as "Angstrom pore"), an insulating membrane, a first medium and a second medium. In one embodiment of the present invention, the pore with an Angstrom size is a small conductance mechanosensitive channel (MscS) Angstrom pore. The pore with an Angstrom size is preferably a heptameric structure with radial symmetry and a cylindrical shape, and the heptameric structure includes 7 side openings and 1 bottom opening. In one embodiment of the present invention, the pore with an Angstrom size has a typical heptameric structure with radial symmetry and a cylindrical shape, and the heptameric structure includes 8 openings, of which 7 equal openings are distributed on the side, and the 8th opening is distributed on the bottom and is formed by 7 subunits; the pore sizes of the above 8 openings can be adjusted. The pore with an Angstrom size allows the analyte to translocate from one side of the insulating membrane to the other side.

[0116] In one embodiment of the present invention, the pores with angstrom size are embedded in the insulating film, and the insulating film (which can also be understood as a complex of the pores with angstrom size and the insulating film) separates the first medium from the second medium, and the pores with angstrom size provide a channel connecting the first medium and the second medium; after applying a driving force between the first medium and the second medium, the analyte located in the first medium interacts with the MscS angstrom pore to form a current (i.e., an electrical signal). In the present invention, the "first medium" refers to the medium where the analyte is located when it is added to the angstrom pore system; the "second medium" refers to the other side of the "first medium" in the two parts of the medium separated by the insulating film. In the present invention, the driving force refers to the force that drives the analyte to interact with the angstrom pore by means of electric potential, electroosmotic flow, concentration gradient, etc.

[0117] The first medium and the second medium may be the same or different, and the first medium and the second medium may include a conductive liquid. The conductive liquid is an aqueous solution of alkali metal halides, specifically sodium chloride (NaCl), lithium chloride (LiCl), cesium chloride (CsCl), potassium chloride (KCl), sodium bromide (NaCl). In one embodiment of the present invention, the concentrations of the conductive liquids contained in the first medium and the second medium are different. In other words, there is a difference in the concentration of the conductive liquid in the first medium and the second medium, which results in a difference in the osmotic pressure on both sides of the insulating membrane. The first medium and / or the second medium may also include a buffer, such as HEPES. The concentration range of the first medium and / or the second medium may be 30mM-3M.

[0118] The insulating membrane refers to a membrane having the ability to carry angstrom pores (or nanopores) and block the ionic current passing through non-angstrom pores (or nanopores). The insulating membrane may include a phospholipid membrane and / or a polymer membrane. Exemplary phospholipid membranes include DPHPC, DOPC, and E. coli lipid, and exemplary polymer membranes include triblock copolymer polymer membranes.

[0119] The present angstrom pore system may include any small conductance mechanosensitive channel described herein, such as wild-type PaMscS (SEQ ID NO: 1), wild-type EcMscS (SEQ ID NO: 2), wild-type TtMscS (SEQ ID NO: 3) and wild-type HpMscS (SEQ ID NO: 4) and their corresponding variants, and the specific sequence information of the above four MscS is shown in Table 4. For example, the small conductance mechanosensitive channel may be mutant PaMscS1 (W130A), mutant PaMscS2 (K180R), mutant PaMscS3 (V271I).

[0120] Table 4: Amino acid sequence information of four MscS

[0121] In a specific embodiment of the present invention, the angstrom system includes two electrolyte chambers, which are separated by an insulating membrane to form a trans compartment and a cis compartment, and the holes of the angstrom are embedded in the insulating membrane, and there are only small-conductance mechanical force-sensitive channels, angstroms, on the insulating membrane to connect the two electrolyte chambers. When an electric potential is applied to the two electrolyte chambers, the electrolyte ions in the solution in the electrolyte chambers move by electrophoresis and pass through the angstrom pores.

[0122] In one embodiment of the present invention, the small conductance mechanosensitive channel (MscS) angstrom pore can be embedded in an insulating membrane, but it retains the ability to change the protein structure in response to mechanical force stimulation of the insulating membrane and changes in the physical state of the insulating membrane. Specifically, mechanical force stimulation includes changes in osmotic pressure on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by microneedles, stimulation of the insulating membrane by negative air pressure, etc. The physical changes of the insulating membrane include changes in the thickness of the insulating membrane, changes in the composition of the insulating membrane, and changes in the surface curvature of the insulating membrane. The change in protein structure includes changing the charge properties and / or pore size of the opening of MscS. Further, the charge properties and / or pore size of the opening changed by the MscS angstrom pore can be used to detect different analytes. The adjustable range of the pore size of the angstrom pore involved in the present invention can be 5-15 angstroms.

[0123] The interaction between the angstrom pore and the analyte

[0124] The analyte may contact the angstrom pore on either side of the insulating film. The analyte may contact either side of the insulating film so that the analyte passes through the channel of the angstrom pore to reach the other side of the insulating film. In this case, the analyte interacts with the angstrom pore when it passes through the insulating film via the channel of the pore. Alternatively, the analyte may contact the side of the insulating film, which may allow the analyte to interact with the angstrom pore, separate from the angstrom pore and remain on the same side of the insulating film. The analyte may interact with the angstrom pore in any manner and at any site. The analyte may also hit the angstrom pore, interact with the angstrom pore, separate from the angstrom pore and remain on the same side of the insulating film.

[0125] During the interaction between the analyte and the angstrom pore, the analyte affects the current flowing through the angstrom pore in a manner specific to the analyte, i.e., the current flowing through the angstrom pore is characteristic for the specific analyte. A control experiment can be performed to determine the effect of a specific analyte on the current flowing through the angstrom pore, and then to identify the specific analyte in the sample or determine whether the specific analyte is present in the sample. More specifically, the current pattern obtained by detecting the analyte can be compared with a known current pattern obtained under the same conditions using a known analyte to identify the presence or absence of the analyte or the concentration, etc.

[0126] The angstrom pore system of the present invention may further include one or more measuring devices for measuring the current flowing through the angstrom pore, such as a patch clamp amplifier or a data acquisition device.

[0127] sample

[0128] The analyte may be present in any suitable sample. The present invention is typically performed on a sample known to contain or suspected of containing the analyte. The present invention may be performed on a sample containing one or more analytes of unknown species. Alternatively, the present invention may confirm the species of the one or more analytes known to be present or expected to be present in the sample.

[0129] The sample can be a biological sample. The present invention can be performed in vitro on a sample obtained from or extracted from any organism or microorganism. The present invention can also be performed in vitro on a sample obtained from or extracted from any virus. Preferably, the sample is a fluid sample. The sample generally includes body fluids. The sample can be a body fluid sample, such as urine, blood, serum, plasma, lymph, cyst fluid, pleural fluid, ascites fluid, peritoneal fluid, amniotic fluid, epididymal fluid, cerebrospinal fluid, bronchoalveolar lavage fluid, breast milk, tears, saliva, sputum or a combination thereof. The sample can be derived from humans or other mammals. The sample can be a non-biological sample. The non-biological sample is preferably a fluid sample, such as drinking water, sea water, river water and reagents for laboratory tests.

[0130] The sample may not be processed before analysis, for example, the analyte may be detected directly in whole blood. The sample may also be processed before analysis, for example, by centrifugation, filtration, dilution, precipitation or other physical or chemical means known in the art.

[0131] In one embodiment of the present invention, the sample is a whole blood sample.

[0132] In one embodiment of the present invention, the sample is a nucleic acid amplification product.

[0133] Method for detecting the presence of nucleic acid in a sample

[0134] The present invention also provides a method for detecting the presence of nucleic acid in a sample. The method comprises: S1 placing a sample in a nucleic acid amplification system and performing nucleic acid amplification, determining the number of substrate nucleotides in the nucleic acid amplification system, and obtaining a nucleic acid amplification product of the sample; S2 adding the nucleic acid amplification product of the sample to an angstrom pore system, wherein the angstrom pore system comprises: an angstrom pore, an insulating membrane, a first medium, and a second medium, wherein the protein angstrom pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the angstrom pore provides a channel connecting the first medium and the second medium, the angstrom pore is an MscS angstrom pore, the angstrom pore has a radially symmetrical and cylindrical heptamer structure, the heptamer structure comprises 7 side openings and 1 bottom opening, and the nucleic acid amplification product of the sample is added to the first medium; S3 applying a driving force between the first medium and the second medium, the remaining nucleotides in the nucleic acid amplification product of the sample interact with the angstrom pore and generate an electrical signal (current); S4 quantifying the electrical signal to obtain the number of the remaining nucleotides; S5 comparing the number of the remaining nucleotides with the number of the substrate nucleotides to determine whether the target nucleic acid exists in the sample. In some embodiments, S1 and S2 can be performed simultaneously or in the same system. Before detection, a threshold value can also be set. For example, only when the number of at least one of the remaining nucleotides is lower than the threshold value, the target nucleic acid is considered to be present in the sample; or only when the number of all types of remaining nucleotides is higher than the threshold value, the target nucleic acid is considered to be absent in the sample.

[0135] The "depletion strategy" of the present invention is actually applicable to a variety of transmembrane pores, and is not limited to the angstrom pores of the present invention. Those skilled in the art can select other transmembrane pores capable of detecting (and distinguishing) different nucleotides to detect the presence or absence of the target nucleic acid based on their understanding of the present invention.

[0136] "Nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in a single-stranded or double-stranded form. "Nucleic acid amplification" of a target nucleic acid refers to the process of constructing a nucleic acid chain that is identical or complementary to at least a portion of a target nucleic acid sequence in vitro, and the nucleic acid amplification process can only occur when the target nucleic acid is present in a sample. In the nucleic acid amplification process, enzymes (such as nucleic acid polymerases, transcriptases) are usually used to produce multiple copies of a target nucleic acid or a fragment thereof, or multiple copies of a sequence complementary to the target nucleic acid or a fragment thereof. After the nucleic acid amplification process occurs, the substrate nucleotides of the nucleic acid amplification system will decrease accordingly as the number of copies increases. Figure 3 and Figure 4 is an example of nucleic acid amplification.

[0137] The principle of the method of the present invention is based on in vitro nucleic acid amplification technology to consume substrate nucleotides in the nucleic acid amplification system. Therefore, common in vitro nucleic acid amplification technologies, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification technology (SDA), transcription-mediated amplification technology (TMA), and loop-mediated isothermal amplification technology (LAMP) can be used in conjunction with the method provided by the present invention.

[0138] In a specific embodiment, the method provided by the present invention can detect whether the new coronavirus nucleic acid is present in a sample.

[0139] In a specific embodiment, the method provided by the present invention can detect whether single-stranded nucleic acid exists in a sample.

[0140] In one embodiment of the present invention, the present invention constructs suitable primers (e.g., specific primers for SARS-CoV-2 nucleic acid) and introduces the primers into a nucleic acid amplification system (including substrate dNTPs, polymerase, reverse transcriptase). If the novel coronavirus nucleic acid is present in the sample, the novel coronavirus nucleic acid is amplified under appropriate conditions, consuming substrate dNTPs and generating multiple copies of the nucleic acid. After the nucleic acid amplification product of the sample is added to the angstrom pore system provided by the present invention, the macromolecular substances (e.g., enzymes, polynucleotides, etc.) in the nucleic acid amplification system cannot pass through the angstrom pore, that is, only free mononucleotides in the nucleic acid amplification system can pass through the angstrom pore and generate a specific current, thereby determining the number of remaining nucleotides to determine whether the target novel coronavirus nucleic acid is present in the sample (i.e., if there is no target novel coronavirus nucleic acid in the sample, the number of remaining nucleotides is closer to the number of substrate nucleotides before nucleic acid amplification; if there is novel coronavirus nucleic acid in the sample, the number of remaining nucleotides is significantly lower than the number of substrate nucleotides before nucleic acid amplification, more specifically, at least one nucleotide in the substrate nucleotide may be completely consumed).

[0141] In one embodiment of the present invention, the present invention constructs a suitable probe (for example, the probe includes a sequence complementary to the target nucleic acid sequence and a polynucleotide sequence) and introduces the probe into a nucleic acid amplification system (including substrate dNTPs and polymerase). If the target nucleic acid sequence exists in the sample, the target nucleic acid sequence is amplified under appropriate conditions, consumes substrate dNTPs and generates multiple copies of the target nucleic acid sequence; more specifically, since the probe also has a polynucleotide sequence (for example, Poly T, Poly A, Poly C, Poly G), after the target nucleic acid sequence binds to the probe, a large amount of substrate nucleotides corresponding to the polynucleotide sequence will be consumed, so the specific consumption of a certain substrate nucleotide can be used to determine whether the target nucleic acid sequence exists in the sample. After the nucleic acid amplification product of the sample is added to the angstrom pore system provided by the present invention, the macromolecular substances (e.g., enzymes, polynucleotides, etc.) in the nucleic acid amplification system cannot pass through the angstrom pore, that is, only free mononucleotides in the nucleic acid amplification system can pass through the angstrom pore and generate specific current, thereby determining the number of remaining nucleotides to determine whether the target nucleic acid sequence exists in the sample (i.e., if there is no target nucleic acid sequence in the sample, the number of remaining nucleotides is closer to the number of substrate nucleotides before nucleic acid amplification; if there is a target nucleic acid sequence in the sample, the number of remaining nucleotides is significantly lower than the number of substrate nucleotides before nucleic acid amplification and the corresponding polynucleotides in the probe are consumed in large quantities. Based on this, different probes can be designed to simultaneously detect different target nucleic acid sequences in the same nucleic acid amplification system.

[0142] Method for detecting drug molecules in samples

[0143] The present invention also provides a method for detecting drug molecules in a sample, the method comprising: S1 adding the sample to an angstrom pore system, the angstrom pore system comprising: an angstrom pore, an insulating membrane, a first medium, and a second medium, wherein the angstrom pore is embedded in the insulating membrane, the insulating membrane separates the first medium from the second medium, the angstrom pore provides a channel connecting the first medium and the second medium, the angstrom pore is an MscS angstrom pore, the angstrom pore has a radially symmetrical and cylindrical heptamer structure, the heptamer structure comprises 7 side openings and 1 bottom opening; the sample is added to the first medium; S2 applying a driving force to the first medium and the second medium, the drug molecules in the sample interact with the angstrom pore and generate an electrical signal; S3 analyzing the electrical signal to further identify the drug molecules in the sample.

[0144] In one embodiment of the present invention, the sample is a body fluid sample. The body fluid sample can be urine, blood, serum, plasma, lymph, cyst fluid, pleural fluid, ascites fluid, peritoneal fluid, amniotic fluid, epididymal fluid, cerebrospinal fluid, bronchoalveolar lavage fluid, breast milk, tears, saliva, sputum or a combination thereof. The sample can be untreated before analysis, for example, the analyte is detected directly in whole blood. Of course, the sample can also be treated before analysis, for example, by centrifugation, filtration, dilution, precipitation or other physical means or chemical means known in the art. The sample referred to in the present invention includes untreated samples and treated samples.

[0145] In one embodiment of the present invention, the detectable range of the drug molecule may be greater than 10 nM (which may also be understood as a detection limit of 10 nM). Preferably, the detectable range of the drug molecule may be 10 nM to 1 mM. If the concentration of the drug molecule is much greater than 10 nM (e.g., 10 mM), its concentration may be diluted to 10 nM to 1 mM.

[0146] In one embodiment of the invention, the drug molecule is a compound. More specifically, "drug molecule" can be a drug with 1000 g / mol or lower molecular weight (e.g., less than 800, 700, 600, 500, 400, 300 or 200 g / mol). Preferably, the drug molecule can be an aminoglycoside antibiotic, such as gentamicin sulfate, neomycin sulfate, sisomicin, etc. In another embodiment of the invention, the drug molecule includes amino acids and salts thereof (including non-drugable amino acids) and peptides.

[0147] In one embodiment of the present invention, the present invention detects drug molecules in a body fluid sample, wherein the detection limit of the drug molecules is 10 nM. In other words, the detectable range of the drug molecules in the body fluid sample may be greater than 10 nM.

[0148] In one embodiment of the present invention, the present invention detects drug molecules in a whole blood sample (also understood as a "blood sample"). After the whole blood sample is added to the angstrom pore system provided by the present invention, the cells (e.g., red blood cells, white blood cells, platelets) and macromolecules (e.g., proteins) in the whole blood sample cannot pass through the angstrom pores, that is, the cells and macromolecules in the whole blood sample will not block the angstrom pores provided by the present invention. However, the drug molecules present in the whole blood sample can pass through the angstrom pores and generate specific currents. The angstrom pores provided by the present invention can sensitively identify the drug molecules at lower concentrations, thereby determining the presence and concentration of the drug molecules in the whole blood sample.

[0149] In one embodiment of the present invention, the method provided by the present invention can be used to continuously monitor the blood concentration of drug molecules in a subject.

[0150] In one embodiment of the present invention, PaMscS2 (K180R) and PaMscS3 (V271I) angstrom pores are used to detect drug molecules in whole blood samples, but other MscS and their corresponding variants are also included in the protection scope of the present invention, based on the fact that the above variants all have the ability to sense and detect drug molecules.

[0151] Specific implementation examples:

[0152] Embodiment 1

[0153] Materials and Methods

[0154] Sodium chloride (NaCl, >99.0%, CAS#7647-14-5), dNTP mixture (>99.0%), dATP (>97%, CAS#1927-31-7), dCTP (>98%, CAS#102783-51-7), dGTP (>98%, CAS#93919-41-6), and dTTP (>98%, CAS#18423-43-3) were purchased from Sangon Biotech. Yeast extract (CAS#8013-01-2), trypsin (CAS#73049-73-7), ampicillin sodium salt (≥98.5%, CAS#69-52-3), Tris (≥99.9%, CAS#77-86-1), imidazole (≥99%, CAS#288-32-4), dodecyl-β-D-maltopyranoside (DDM) (≥99%, CAS#69227-93-6), isopropyl-β-D-thiogalactoside (IPTG) (≥99%, CAS#367-93-1), phenylmethylsulfonyl fluoride (Phenylmethylsulfonyl fluoride) fluoride, PMSF) (≥99.%, CAS#329-98-6), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (>99.5%, CAS#7365-45-9) were purchased from Sigma-Aldrich. Escherichia coli extracted phospholipids were purchased from Avanti. PrimeSTAR HSDNA polymerase was purchased from TaKaRa. pUC57 vector plasmid, DNA template, miRNA-21, and AFP aptamer were synthesized by Sangon Biotech, and their sequence information is listed in Table 1.

[0155] Table 1 Sequences of miR21 and AFP aptamers

[0156] Expression and purification of wild-type and mutant PaMscS:

[0157] The gene of PaMscS from the genomic DNA of Pseudomonas aeruginosa was amplified by polymerase chain reaction (PCR) using gene-specific primers. The gene was inserted into the plasmid using ClonExpress II One Step Cloning Kit (Vazyme). Escherichia coli BL21 (DE3) cells containing the plasmid of the PaMscS gene were cultured and expressed and purified in Luria-Bertani (LB) medium at 37°C in the presence of 50 μg / mL ampicillin. The peak value was determined by SDS-PAGE analysis. It is particularly noted that the expression and purification steps of the wild-type and mutant proteins in the present invention are the same, except that there are differences in the plasmid synthesis stage due to the sequence differences between the wild-type protein and the mutant protein.

[0158] The experimental team of the present invention revealed the structure of the protein angstrom pore through modeling, which is a typical heptamer with radial symmetry and cylinder-like shape. It contains 8 openings, 7 on the side and 1 at the bottom. The N-terminal residues 1-13 are too flexible to be resolved in the model. Topologically, PaMscS can be divided into two parts, the transmembrane region and the large cytoplasmic part. Each monomer produces three N-terminal transmembrane helices, including TM1 (residues 17-52), TM2 (residues 58-83) and TM3 (residues 90-122). The C-terminal cytoplasmic region can be divided into the middle β domain and the COOH terminal domain. TM1 and TM2 in each subunit are arranged together in an antiparallel direction, TM1 passes through the double membrane outside the channel and TM2 forms the central layer, thus forming a permeation path around the channel axis. The TM3 helix can be described as two helical fragments, TM3a and TM3b, separated by a distinct kink (kink) ~53° at Gly108, which is a conserved residue in homology. TM3a, like TM1, passes through the membrane with a different deflection, while TM3b returns to the cytoplasm and interacts with the cytoplasmic region. In addition, the seven subunits form a The central pore senses tension and is associated with conformational changes. Comparing the MscS structures of Pseudomonas aeruginosa and Escherichia coli, the tilt angles of TM1 and TM2 of the former are smaller than those of the latter, which leads to a large deflection of the TM region, especially the loop between TM1 and TM2. In the cytoplasmic region, the middle β domain (residues 123-172) contains 5 β chains, which are tightly connected to the β chains of other different subunits. And the C-terminal domain (residues 177-273) is composed of 5 β chains and 2 α helices, which is a mixed structure. Between these two domains of adjacent monomers, there are 7 equal openings on the side, which are clearly visible, with a radius of about It is proposed to be responsible for ion permeation in EcMscS. In addition to these portals, an eighth opening exists at the base of the protein, represented by seven β-strands with a narrowest radius of In all sizes, extending to The PaMscS2 is parallel to the sevenfold axis and has a width in the perpendicular direction. The structure of PaMscS is similar to that of EcMscS in the closed state (PDB: 2OAU), and the TM domain has more than 101 rmsd. C α atoms, but in the open state (PDB: 2VV5), there is a large difference in the TM region, with an rmsd of These results suggest that the conformation of PaMscS in the structure reflects the closed state. Overall, the unique and elaborate structure of the PaMscS angstrom pore shows great potential for detection.

[0159] Site mutation:

[0160] The DNA sequence corresponding to the corresponding amino acid site is modified (including direct synthesis or PCR mutation after DNA sequence modification), and the DNA sequence at the target mutation site is modified to the DNA sequence corresponding to the mutant protein. The mutant protein of the mutant PaMscS protein angstrom may include 130A, 130H, 180R, 271I, 130S or 130P.

[0161] Merging and single channel recording of membranes:

[0162] The experiments were performed in a vertical sample cell provided by Warner Instruments. If not specifically mentioned, all current traces were recorded by a HEKA EPC 10USB patch clamp amplifier with a sampling frequency of 9900 Hz. 1 μL of 25 mg / mL E. coli membrane was pre-coated on the 150 μm orifice of the cup, and then 1 mL of electrolyte solution (-trans end: 100 mM NaCl, 10 mM HEPES, pH 7.0; -cis end: 300 mM NaCl, 10 mM HEPES, pH 7.0) was added to both sides of the sample cell. Then about 2 / 3 of the electrolyte solution of the sample cell was aspirated from the -cis end with a 1 mL pipette. When the average current was close to 0 pA, the electrolyte solution was driven to the -cis side of the sample cell to form a planar phospholipid bilayer. After the phospholipid membrane was formed, the PaMscS1 protein solution was added to the -cis end. When PaMscS1 was embedded in the planar phospholipid bilayer, the current changed significantly. After the protein was embedded, 1 mL of solution was replaced and subsequent experiments were performed.

[0163] Single Nucleotide Detection:

[0164] Different groups of amplification products were detected by MscS angstrom pores. Different samples were added to the -cis end, and the current was recorded and observed at +50 mV for 20 minutes. When a stable PaMscS1 angstrom pore was formed on the planar phospholipid membrane, the single nucleotide to be detected was added to the -cis end of the sample pore, and then a voltage was applied and the current signal was recorded.

[0165] Collection and processing of coronavirus clinical samples:

[0166] Clinical samples of SARS-CoV-2 patients were collected through throat swabs (patient numbers: 1-15) and blood (patient numbers: 16-22), and cDNA was obtained after reverse transcription.

[0167] RNA reverse transcription and PCR amplification:

[0168] The SARS-CoV-2 RNA reverse transcription amplification system of the present invention is as follows: random hexamer (60 μM) and anchor poly T (23): 1 μL, dNTP mixture (10 mM each): 1 μL, RNA sample: 11 μL. The reaction was incubated in a thermal cycler at 65°C for 5 minutes. The sample was immediately placed on ice for rapid cooling for >1 minute. Then, in a clean pre-PCR hood, the following reagents were mixed with the sample: 5X SuperScript IV buffer: 4 μL, DTT (100 mM): 1 μL, RNaseOUT RNase inhibitor: 1 μL, Superscript IV reverse transcriptase: 1 μL. The sample was incubated in a thermal cycler using a program of 42°C for 50 minutes and 70°C for 10 minutes to obtain cDNA. The cDNA PCR amplification system in the experiment of the present invention is as follows: ddH2O: 26.5μL, 5×PrimeSTAR buffer (Mg2+Plus): 10μL, dNTP mixture (2.5mM): 4μL, primer 1 (forward primer ORF P1, 10μM): 2μL, primer 2 (reverse primer ORF P2, 10μM): 2μL, PrimeSTAR HSDNA polymerase (2.5U / μL): 0.5μL, cDNA sample: 5μL. The amplification procedure is as follows: preheat at 95°C for 5 minutes, thermal denaturation at 98°C for 10 seconds. Anneal at 55°C for 15 seconds, then extend at 72°C for 12 seconds. Repeat the cycle for a total of 35 times. The above primers were synthesized independently by this research team, and the sequences are as follows: ORF P1:TTGTTTGAATAGTAGTTGTCTGA(SEQ ID NO:7) ORF P2:TCAACTCAATATGAGTATGGTACTG(SEQ ID NO:8)

[0169] Reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) and detection:

[0170] Perform RT-LAMP reaction containing the following system: ddH2O: 4.1 μL, Colorimetric LAMP2X Master Mix (DNA & RNA): 12.5 μL, F3 (20 μM): 0.2 μL, B3 (20 μM): 0.2 μL, FIP (20 μM): 1 μL, BIP (20 μM): 1 μL, LoopF ​​(20 μM): 0.5 μL, LoopB (20 μM): 0.5 μL, Template: 5 μL. LAMP reaction was run at 60°C for 30 minutes.

[0171] Nucleic Acid Amplification and Detection:

[0172] The nucleic acid amplification system of the present invention is as follows: ddH2O: 64.6μL, 5×PrimeSTAR buffer (Mg2+Plus): 20μL, dNTP mixture (10mM each): 6μL, primer 1 (miRNA21, 100μM): 0.4μL, primer 2 (AFP adapter, 10μM): 4μL, template 1 (extraction, poly T): 2μL, template 2 (poly C, 1μM): 2μL, PrimeSTAR HSDNA polymerase (2.5U / μL): 1μL. The amplification procedure is as follows: preheat at 95°C for 5min and heat denaturation at 98°C for 10s. Anneal at 60°C for 15 seconds, then extend at 68°C for 23 seconds. Repeat the cycle 30 times in total, and the nucleic acid amplification results are as follows. Fig.13 shown.

[0173] Electrobiology data analysis:

[0174] In the present invention, electrobiological data were processed by Clampfit software and plotted using Origin software.

[0175] Embodiment 2

[0176] Electrophysiological detection and dNTP detection based on PaMscS angstrom pore:

[0177] The basic function of MscS is a fast on / off switch that responds to mechanical stimuli, such as changes in membrane tension during osmotic stress. The cytoplasmic domain of MscS functions as a molecular sieve that balances the loss of osmolytes during osmoadaptation. In the protein angstrom pore of the present invention, the seven side pores from the cytoplasmic region play a key role in the translocation of ions and solutes. Therefore, the side pore mutants PaMscS1 (W130A) and PaMscS2 (K180R) were selected for subsequent studies due to their low background noise ( Figure 5 , Figure 6 AC). In electrophysiological experiments, the purified protein was added to the -cis end of the electrophysiological device ( Figure 1 A). When the PaMscS mutant channel was embedded in a bilayer lipid membrane (BLM, a type of insulating membrane), a stable channel current jump was observed at a voltage of +50 mV ( Figure 1 B). The channel conductance of PaMscS1 remains stable at voltages ranging from -50 mV to +50 mV ( Figure 1 C), and when the voltage is higher than +90 mV, the gating probability of PaMscS1 increases ( Figure 7The conductance of the PaMscS1 angstrom pore is 0.64 ± 0.02 nS (n = 91, peak ± SD of Gaussian fitting, -cis end: 300 mM NaCl, -trans end: 30 mM NaCl), and the conductance distribution of the PaMscS2 angstrom pore is 34.9 ± 7.0 pA (mean ± SD, from 18 independent insertion events) ( Figure 1 D) The ion transport results of PaMscS1 showed that PaMscS1 has better selectivity for Br- ( Figure 8 ).

[0178] When the PaMscS1 Å hole is inserted into the BLM and dNTPs are present in the -cis end, the translocation signal of dNTPs can be observed under positive voltage. The translocation frequency of dNTPs increases with the increase of voltage ( Fig. 9 Both PaMscS1 and PaMscS2 were analyzed for dNTP mixture detection (dNTPs concentration: 0.2mM, voltage: +50mV, -cis end: 300mMNaCl, -trans end: 30mMNaCl). Clear differences in the blockade current distributions were observed between the two mutants, indicating that the translocation of dNTPs is associated with the side pores of the PaMscS angstrom pore ( Figure 1 E), that is, under the same detection conditions, the distribution of the blocking current of dNTPs for PaMscS1 and PaMscS2 angstroms is different. Specifically, the blocking rate of the PaMscS1 angstrom pore for the four dNTPs mixtures shows three peaks, while the blocking rate of the PaMscS2 angstrom pore for the four dNTPs mixtures shows two peaks. Because the difference between the PaMscS1 and PaMscS2 mutations lies in the difference in the amino acids of the side pores, it is speculated that the detection signal of dNTPs is related to the side pores. Since PaMscS1 has a better discrimination effect on dNTP mixtures, it is more suitable for distinguishing dNTP mixtures. As for PaMscS2, it exhibits a more stable channel conductance and a relatively higher membrane fusion efficiency, so it is more suitable for subsequent rapid diagnosis ( Figure 6 AC). The wild-type PaMscS angstrom pore showed two peaks in blocking rate for the four dNTPs mixtures ( Fig.29 ). The current trajectory and residence time distribution of PaMscS1 detecting single nucleotides are shown in Figure 2. Fig.10 As shown in AD.

[0179] Compared with the currently reported nanopores containing am7βCD, MoS2 and α-Hederin, although the detection accuracy of the PaMscS1 angstrom pore is lower than that of the best reported biological nanopore containing am7βCD conjugate (i.e., constructed using α-hemolysin mutant protein and 6-amino-6-deoxy-β-cyclodextrin aptamer), the translocation speed is comparable to that of solid-state nanopores. In the single-stranded DNA (ssDNA) detection experiment, 50μM ssDNA was detected under the buffer conditions of 30mM NaCl / 300mM NaCl and +50mV bias voltage, and no translocation events were observed due to its narrow channel size ( Fig.11 ). Therefore, the PaMscS mutant angstrom pore has the potential to be a useful small molecule sensor.

[0180] Embodiment 3

[0181] Selective tuning of the PaMscS1 angstrom pore for optimized dNTPs detection:

[0182] Considering the mechanical sensitivity of PaMscS1 angstrom pore, the selectivity of PaMscS1 angstrom pore was adjusted by applying different osmotic pressure differences. In order to maintain the constant charge characteristics of dCTP and dGTP under different osmotic pressure differences, the concentration of the conductivity buffer at the -cis end was kept at 300mM and the concentration of the conductivity buffer at the -trans end was changed to change the osmotic pressure difference. The detection ability of PaMscS1 angstrom pore for large dGTP and small dCTP was tested under three osmotic pressure difference conditions, including symmetric conditions ( Figure 2 A, 300 mM NaCl / 300 mM NaCl, +50 mV bias voltage), low osmotic pressure difference condition ( Figure 2 B, 100 mM NaCl / 300 mM NaCl, +50 mV bias voltage) and high osmotic pressure difference conditions ( Figure 2 C, 30 mM NaCl / 300 mM NaCl, +50 mV bias voltage). Under symmetric osmotic pressure conditions, the translocation frequency of dCTP increased from 0.16 ± 0.03 s -1 Increased to 0.22±0.07s -1 , while dGTP from 0.09±0.02s -1 Change to 0.07±0.003s -1 Under low osmotic pressure difference (LOD) conditions, the translocation frequency of dCTP increased from 0.34 ± 0.1 s -1 Increased to 0.67±0.14s -1 , while dGTP from 0.06±0.01s -1 Increase to 0.3±0.04s -1Under high osmotic pressure difference (HOD) conditions, the translocation frequency of dCTP increased from 0.12 ± 0.04 s -1 Increased to 0.22±0.07s -1 , while dGTP from 0.37±0.08s -1 Increased to 1.12±0.12s -1 ( Figure 2 D, n = 3 per experiment, mean ± SEM). Figure 2 E summarizes the detection of dGTP and dCTP, and it is concluded that the low osmotic pressure difference condition shows the highest increase in translocation events for dCTP, while the high osmotic pressure difference condition shows the highest increase in translocation events for dGTP ( Figure 2 E). Compared with the reduced capture efficiency of dCTP under high osmotic pressure conditions, low osmotic pressure difference conditions show balanced capture capacity for both dCTP and dGTP. Given that the size and charge characteristics of dGTP and dCTP remain constant under given experimental conditions, and the channel size of the MscS family (e.g., EcMscS, HpMscS, AtMsL1 proteins, etc.) can change under different pressures, osmotic pressure conditions, or membrane potentials, the experimenters can conclude that the difference in selectivity of PaMscS1 angstrom pores for dNTPs is caused by the change in channel size under different osmotic pressure difference conditions.

[0183] Embodiment 4:

[0184] Detection of SARS-CoV-2 clinical samples by PaMscS2:

[0185] Rapid and simple detection of SARS-CoV-2 nucleic acid is an important preventive measure against the spread of SARS-CoV-2. Here, the researchers used specific primers for SARS-CoV-2 Orf1ab (cDNA) to detect SARS-CoV-2 ( Figure 3 A). PaMscS2 angstrom pores were used for detection because of their high membrane fusion efficiency. The target sequence was 172 bp, and fragment analysis of the amplified product showed that the primers could be used for amplification of the target gene (Table 2). The SARS-CoV-2 Orf1ab gene was synthesized and the gradient concentration of the SARS-CoV-2 Orf1ab gene was detected. The synthesized SARS-CoV-2 Orf1ab gene could be detected in the concentration range of 10^3 copies / mL to 10^11 copies / mL ( Figure 3B). Then, 22 clinical samples were tested, including 15 samples from confirmed patients and 7 samples from healthy controls. The 15 positive samples and 6 negative samples (patient numbers: 1-15, 17-22) tested by Empiric pore all showed results consistent with clinical tests (Table 3), and 1 negative sample was diagnosed as a false positive result (patient number: 16). The specificity of this method was 86% and the sensitivity was 100% ( Figure 3 C). As a nanodevice for nucleic acid amplification monitoring, the PaMscS mutant angstrom system can be combined with various NAATs (Nucleic Acid Amplification Tests, nucleic acid amplification detection) such as polymerase chain reaction and chain displacement amplification ( Fig.12 ) to detect target genes ( Figure 3 D), the pore also has the potential to monitor the reverse transcription process, which can achieve rapid and amplification-free detection of target RNA.

[0186] Table 2: Fragment length and amplification product concentration

[0187] Table 3: Ct values ​​and angstrom pore detection results of clinical samples

[0188] Embodiment five:

[0189] Detection of multiple biomarkers through PaMscS1 angstrom pores:

[0190] The researchers designed a dNTP barcode probe differentiation strategy and verified its application in the detection of multiple biomarkers through the PaMscS1 angstrom pore. Two probes were designed to bind to the target DNA sequence and cause specific dNTPs consumption in the chain polymerization reaction, including the miR21 probe (probe A): including a sequence complementary to miR21 and a polyT barcode sequence; the AFP aptamer probe (probe B): including a sequence complementary to the AFP aptamer and a poly C barcode sequence. When probe A or probe B is present in the sample, the polymerase chain reaction can be activated to consume dATP or dGTP in the reaction system ( Figure 4 A). The control sample without target sequence, the sample with miR21, the sample with AFP aptamer, and the sample with both miR21 and AFP aptamer were tested. The corresponding current traces and blockade current distributions are shown in Figure 2. Figure 4 B and 4C. It can be observed that in the control group (samples without miR21 and AFP aptamer), dATP (δf dATP =f dATP / f背景 The relative increase in the frequency of translocation events of dGTP (δf dGTP =f dGTP / f 背景 ) had a relative increase in the frequency of translocation events of 1.8 ± 0.03. In samples with miR21, δf dATP was significantly lower than that of the control group (1.4±0.1, mean±SEM). dGTP For samples with both miR21 and AFP aptamer, δf dATP (1.1±0.2, mean±SEM) and δf dGTP (1.3±0.2, mean±SEM) were decreased ( Figure 4 D) These results indicate that PaMscS1 can detect single or multiple biomarkers simultaneously (n ≥ 3 per experiment).

[0191] Embodiment six:

[0192] A strategy to enhance the signal:

[0193] A. Enhance the detection limit of the object to be detected by ion regulation, specifically for dNTPs, by adding divalent cations such as nickel ions and cobalt ions to the cytoplasmic end of the angstrom pore involved in the present invention, the detection limit of dNTPs can be improved; B. Enhance the signal-to-noise ratio by regulating the osmotic difference of the conductive liquid, specifically by increasing the concentration of the conductive liquid, the ability to distinguish drug molecules with similar structures can be improved, and by increasing the osmotic difference of the conductive liquid on both sides of the phospholipid membrane, the detection effect of dGTP can be improved.

[0194] Embodiment seven:

[0195] Drug Testing

[0196] 1. Drug measurement by LC-MS:

[0197] LC-MS and LC-MS / MS analyses were performed on a Shimadzu ultrafast liquid chromatography system (UFLC, Shimadzu) and an AB SCIEX Qtrap 5500 mass spectrometer equipped with a Turbo Spray ion source. Chromatographic and mass spectrometric data were collected and analyzed using Analyst 1.6.2 software (AB SCIEX, USA).

[0198] Chromatographic separation was achieved on a Waters ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm ID, 1.7 μm). The mobile phase consisted of water (A) and acetonitrile (B) with a gradient elution as follows: 0-1.0 min, 10-90% B; 1-2.0 min, 90% B. The flow rate was 0.5 mL / min. The column temperature and the temperature of the autosampler were maintained at 35°C and 15°C, respectively. The injection volume was 1 μL.

[0199] In MS / MS analysis, positive ionization mode was used for sample detection, with the following optimized mass spectrometry parameters: ion spray voltage, 5500 V; declustering voltage, 100 V; temperature, 500° C. MRM (multiple reaction monitoring) mode was selected to quantify gentamicin sulfate and IS (internal standard), with ion pairs of 450.2-160.1, 464.2-160.1, 478.2-157.1 and 265.2-232.2, respectively.

[0200] 2. Continuous monitoring of gentamicin sulfate from a dialysis device connected to a blood vessel in a living rat:

[0201] Male Sprague-Dawley rats (250–300 g) were provided by Chengdu Dashuo Experimental Animal Co., Ltd. All animal experiments in the present invention were approved by the Ethics Committee of West China Hospital, Sichuan University (approval number 2021885A).

[0202] Rats (n=1) were anesthetized with 2% pentobarbital, and the left femoral vein was isolated and cannulated to provide an intravenous injection port. Next, an initial 0.4 mL of heparin solution (250 U / mL) was injected through the catheter, followed by 0.1 mL every 40 minutes to prevent blood clot formation during monitoring. The left femoral artery was then isolated, cannulated, and immediately connected to the device through a pre-designed tube with dialysis membrane. After the air in the device was expelled by the blood flow, the tube was connected to the intravenous catheter to form a stable loop. For continuous monitoring, a baseline signal was first recorded in the absence of the target drug, and then a specific concentration of gentamicin sulfate was injected at a slow rate through the intravenous catheter. For interval measurement of blood concentrations, a similar loop was established without either the device or the dialysis membrane. Blood samples were collected from the arterial catheter at 0, 15, 30, 45, and 60 minutes, and drug concentrations were measured using PaMscS3 (V271I) angstroms. After each experiment, the rats were killed by cervical dislocation.

[0203] 3. Whole blood test:

[0204] Ten microliters of rat blood was collected and added to a sample tank fused with an angstrom hole (-cis end). A bias voltage was applied and the signal frequency within a certain period of time was recorded. The signal frequency was then subtracted from the blank blood control frequency. The concentration of the molecule was calculated based on the standard curve of the detected molecule.

[0205] result:

[0206] 1. Single-molecule drug biosensing based on PaMscS angstrom pores:

[0207] Based on the channel structure of the PaMscS angstrom pore, small molecule drugs (molar mass less than 1000 g / mol) were selected for detection. Gentamycin sulfate (MW: 561.65) and neomycin sulfate (MW: 712.72) were tested for quantitative determination because their large-scale use in clinical practice indicates an urgent need for convenient TDM (therapeutic drug monitoring). The detection experiments of gentamicin sulfate and neomycin sulfate were carried out under the electrolyte conditions of 300mMNaCl (-cis end) and 30mMNaCl (-trans end), 10mM HEPES, pH 7.0, and the voltage of drug detection was -50mV. After the drug was added to the detection system, an obvious blocking current signal ( Fig.14 A. 14B, Fig.17 , Fig.18 The standard curve of gentamicin sulfate showed a linear detection range of 10 nM to 10 μM (N=3), and the 2D density plot of a typical gentamicin sulfate signal showed a peak blockade current of 11.57±0.02 pA and a peak dwell time of 1.33±0.02 ms ( Fig.14 C, peak value of Gaussian fit, 878 blockade events). The standard curve of neomycin sulfate showed a linear detection range of 100 nM to 100 μM (N=3), and the 2D density plot of a typical neomycin sulfate signal showed a peak blockade current of 9.44±0.02 pA and a peak dwell time of 1.06±0.01 ms ( Fig.14 D, peak of Gaussian fit, 883 blockage events). Higher drug concentrations may lead to severe blockage of the channel and make drug concentration calculation difficult ( Fig.19 In addition to gentamicin sulfate and neomycin sulfate, the PaMscS angstrom pore can also sense other drugs such as sisomicin (MW: 447.53) and pyrophosphate (MW: 177.975) by single molecule.

[0208] In order to evaluate the detection accuracy of PaMscS3(V271I) angstrom pore for drugs, LC-MS was used to measure the concentration of gentamicin sulfate. For 1.5μM gentamicin sulfate sample, PaMscS3(V271I) angstrom pore and LC-MS showed similar detection results, indicating that the detection of PaMscS3(V271I) angstrom pore has good accuracy ( Fig.14 E).

[0209] 2. Measurement of drug concentration in whole blood samples:

[0210] Blood is the main medium for therapeutic drug monitoring (TDM), but the composition of whole blood is complex, which can cause serious interference to nanopore detection. The commonly used nanopore MspA-2NN was blocked after adding 10μL of whole blood sample to the -cis end (the volume of the -cis end and -trans end was 1mL), and the probability of opening the channel at +100mV within 300s was only 5%±4.7% ( Fig. 20 , electrolyte conditions were -cis end: 300mM NaCl, -trans end: 300mM NaCl, 10mM HEPES, pH7.0, N=3). In contrast, the PaMscS2 angstrom pore can maintain channel openness even when 20μL whole blood is added to the -cis end, and the probability of opening the channel at +100mV within 300s is 99%±1% ( Fig.15 A, 15B, 15C, electrolyte conditions: -cis end: 130 mM NaCl, -trans end: 130 mM NaCl, 10 mM HEPES, pH 7.0, N = 3). Considering the robust detection ability of PaMscS3 (V271I) angstrom pore, at different time intervals (0 min, 15 min, 30 min, 45 min and 60 min) after injection of 4 mg / mL gentamicin sulfate, Fig.21 , Fig. 22 ) to directly measure the blood concentration of gentamicin sulfate in rats. The gentamicin sulfate standard curve ranges from 0 to 3 μM and is used to calculate the drug concentration ( Fig.15 D, N≥3). Among the 5 monitoring points, the drug concentration was the highest at 15 minutes, and the concentration at 60 minutes decreased to the pre-injection level (0 minutes) ( Fig.15 E, N ≥ 3). The drug concentration trend measured by PaMscS3 (V271I) angstrom pores is consistent with the pharmacokinetic law, indicating that PaMscS angstrom pores can accurately measure changes in drug concentration in living rats. Interestingly, the blocking current distribution of gentamicin sulfate shows two peaks at a higher negative voltage in a 130 mM NaCl buffer ( Fig.23), while the single component sisomicin showed a blocking current peak under the same conditions ( Fig.24 ), which indicated that the two blocked current peaks of gentamicin sulfate might be related to its multiple components.

[0211] 3. Continuous monitoring of drugs by a dialysis device connected to the blood vessels of living rats:

[0212] Since drug metabolism rates vary greatly among different patients, especially critically ill patients, it is difficult to meet the needs of precision medicine using interval TDM technology. Therefore, continuous monitoring of drug concentrations is very necessary. In order to achieve long-term monitoring of drug concentrations in living animals, experimenters introduced dialysis membranes to avoid blood consumption. During the TDM process, a small amount of blood flows through a catheter to the dialysis device and then flows back into the body. Small molecule drugs in the blood can penetrate into the conductive liquid at the -cis end through the dialysis device, and the blood is basically not consumed ( Fig.16 A). The standard curve of gentamicin sulfate ranges from 0 to 30 μM and is used for calculation of drug concentrations for continuous monitoring ( Fig.16 B). In the feasibility verification experiment in living rats, based on a simple dialysis device, a clear signal of gentamicin sulfate could be continuously observed until 3 hours after injection ( Fig.16 C). Different doses of gentamicin sulfate, including 4 mg / kg and 20 mg / kg, in rats can be distinguished by the angstrom monitoring device ( Fig.16 D) These results demonstrate that this system can continuously monitor drug concentrations in living animals with minimal losses.

[0213] Embodiment eight:

[0214] Electrophysiological detection based on EcMscS angstrom pore

[0215] When wild-type EcMscS channels were embedded in a bilayer lipid membrane (BLM), a stable channel current jump was observed at a voltage of +100 mV ( Fig.25 ). The wild-type EcMscS channel current remained stable at voltages ranging from -100 mV to +100 mV ( Fig.26 The conductance of the wild-type EcMscS angstrom pore is 0.334±0.028nS (-cis end: 300mM NaCl, -trans end: 30mM NaCl) ( Fig. 27 ). Fig.28 ac show the structures of EcMscS, TtMscS and HpMscS, respectively, which are highly similar to the structure of PaMscS, that is, they are all radially symmetrical and cylindrically shaped heptamer structures. Fig.28 ac and Fig.28d further compared the sequences of PaMscS with EcMscS, TtMscS, and HpMscS. The results showed that EcMscS, TtMscS, HpMscS and PaMscS had certain homology, but this homology was not highly homologous. The similarity between EcMscS and PaMscS was only 60%, but both of them had the ability to detect analytes. Therefore, those skilled in the art can understand that the key to determining that bacterial MscS can be used as an angstrom pore to detect analytes lies in its radially symmetrical and cylindrical heptamer structure and channel pore size, not just homology.

[0216] Embodiment nine:

[0217] Amino acid detection based on PaMscS angstrom pore

[0218] In this example, PaMscS1 is used as an example to detect amino acids. The detection experiment of glutamate (10mM) was carried out under the electrolyte conditions of 300mMNaCl (-cis end) and 30mMNaCl (-trans end), 10mM HEPES, pH 7.0, and the voltage of drug detection was -50mV. The current trace of glutamate is shown in Fig.30 shown.

[0219] In addition to single amino acids, the angstrom pores of the present invention can also detect short peptides (e.g., dipeptides). Fig.31 As shown in the left figure, the amino acid to be tested is dehydrated and condensed with an aspartic acid carrier to form a dipeptide. The formed dipeptide is detected under the electrolyte conditions of 300mMNaCl (-cis end) and 30mMNaCl (-trans end), 10mM HEPES, pH 7.0, and the current signal generated is compared with the specific current signal of the amino acid that has been tested to determine the type of the amino acid to be tested.

[0220] Summarize:

[0221] In the present invention, the experimenters studied a new category of sub-nanochannel PaMscS as a single-molecule sensor. Structural information and electrophysiological tests of wild-type and mutant PaMscS angstrom pores confirmed the ability to directly detect dNTPs. Depending on the size of the analyte, the selectivity of the angstrom pore can be adjusted in situ to obtain the best detection efficiency. Compared with the monitoring of the synthesized nucleic acid products added in NAAT, the PaMscS angstrom pore can be used to directly measure the consumption of DNA components during DNA amplification, and the change is significantly greater than that of DNA products. According to this strategy, SARS-CoV-2 clinical specimens were detected with a specificity and sensitivity of 86% and 100%, respectively. Using this strategy, two target biomarkers including miR21 and AFP aptamers were also detected simultaneously by dNTP barcode probes, indicating that the PaMscS angstrom pore can be used for coded detection of multiple biomarkers. This angstrom-level pore can also achieve direct detection of low molecular weight molecules (such as amino acids and drugs).

[0222] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.

[0223] References 1. Liu, H. & Johnston, APRA Programmable Sensor to Probe the Internalization of Proteins and Nanoparticles in Live Cells. Angewandte Chemie International Edition 52, 5744–5748 (2013). 2.Li,X.et al.Plant DNA barcoding: from gene to genome.BiologicalReviews90,157–166(2015). 3. Wilson, PM et al. A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleosidetriphosphates. Nucleic Acids Research 39, e112–e112 (2011). 4.Fuller,C.W.et al.Real-time single-molecule electronic DNAsequencing by synthesis using polymer-tagged nucleotides on ananoporearray.Proceedings of the National Academy of Sciences of the United States ofAmerica113,5233–5238(2016). 5.Butler,T.Z.,Pavlenok,M.,Derrington,I.M.,Niederweis,M.&Gundlach,J.H.Single-molecule DNA detection with an engineered MspA proteinnanopore.Proceedings of the National Academy of Sciences105,20647–20652(2008). 6.Goyal,P.et al.Structural and mechanistic insights into thebacterial amyloid secretion channel CsgG.Nature516,250–253(2014). 7.Cao,C.et al.Mapping the sensing spots of aerolysin for singleoligonucleotides analysis.Nature Communications9,2823(2018). 8.Wendell,D.et al.Translocation of double-stranded DNA throughmembrane-adapted phi29 motor protein nanopores.Nature Nanotechnology4,765–772(2009). 9.Manrao,E.A.et al.Reading DNA at single-nucleotide resolution with amutant MspA nanopore and phi29 DNA polymerase.Nature Biotechnology30,349–353(2012). 10.Bowden,R.et al.Sequencing of human genomes with nanoporetechnology.Nature Communications10,1869(2019). 11.Wang,Y.,Zheng,D.,Tan,Q.,Wang,M.X.&Gu,L.-Q.Nanopore-based detectionof circulating microRNAs in lung cancer patients.Nature Nanotechnology6,668–674(2011). 12.Thakur,A.K.&Movileanu,L.Real-time measurement of protein–proteininteractions at single-molecule resolution using abiological nanopore.NatureBiotechnology37,96–104(2019). 13.Astier,Y.,Braha,O.&Bayley,H.Toward single molecule DNA sequencing:Direct identification of ribonucleoside and deoxyribonucleoside 5′-monophosphates by using an engineered protein nanopore equipped with amolecular adapter.Journal of the American Chemical Society128,1705–1710(2006). 14.Clarke,J.et al.Continuous base identification for single-moleculenanopore DNA sequencing.Nature nanotechnology4,265–70(2009). 15.Jeong,K.-B.et al.Alpha-Hederin Nanopore for Single NucleotideDiscrimination.ACS Nano13,1719–1727(2019). 16.Venta,K.et al.Differentiation of Short,Single-Stranded DNAHomopolymers in Solid-State Nanopores.ACS Nano7,4629– 4636(2013). 17.Garaj,S.et al.Graphene as a subnanometre trans-electrodemembrane.Nature467,190–193(2010). 18.Booth,I.R.&Blount,P.The MscS and MscL Families of MechanosensitiveChannels Act as Microbial Emergency ReleaseValves.Journal of Bacteriology194,4802–4809(2012). 19.Akitake,B.,Anishkin,A.&Sukharev,S.The“Dashpot”Mechanism ofStretch-dependent Gating in MscS.The Journal ofGeneral Physiology125,143–154(2005). 20.Bass,R.B.Crystal Structure of Escherichia coli MscS,a Voltage-Modulated and Mechanosensitive Channel.Science298,1582–1587(2002). 21.Lee,J.-Y.,Na,I.Y.,Park,Y.K.&Ko,K.S.Genomic variations betweencolistin-susceptible and-resistant Pseudomonasaeruginosa clinical isolatesand their effects on colistin resistance.Journal of AntimicrobialChemotherapy69,1248–1256(2014). 22.Machiyama,H.,Tatsumi,H.&Sokabe,M.Structural changes in thecytoplasmic domain of the mechanosensitive channel MscSduringopening.Biophysical journal97,1048–57(2009). 23.Feng,J.et al.Identification of single nucleotides in MoS2nanopores.Nature Nanotechnology10,1070–1076(2015). 24.Gamini,R.,Sotomayor,M.,Chipot,C.&Schulten,K.Cytoplasmic DomainFilter Function in the Mechanosensitive Channel ofSmallConductance.Biophysical Journal101,80–89(2011). 25.Perozo,E.&Rees,D.C.Structure and mechanism in prokaryoticmechanosensitive channels.Current Opinion in StructuralBiology13,432–442(2003). 26.Maksaev,G.&Haswell,E.S.MscS-Like10 is a stretch-activated ionchannel from Arabidopsis thaliana with a preference foranions.Proceedings ofthe National Academy of Sciences109,19015–19020(2012). 27.Rozevsky,Y.et al.Quantification of mRNA Expression Using Single-Molecule Nanopore Sensing.ACS nano acsnano.0c06375(2020).doi:10.1021 / acsnano.0c06375 28.Ouldali,H.et al.Electrical recognition of the twenty proteinogenicamino acids using an aerolysin nanopore.Naturebiotechnology38,176–181(2020). 29.LEI,J.&FRANK,J.Automated acquisition of cryo-electron micrographsfor single particle reconstruction on an FEI Tecnaielectronmicroscope.Journal of Structural Biology150,69–80(2005). 30.Zheng,S.Q.et al.MotionCor2:anisotropic correction of beam-inducedmotion for improved cryo-electron microscopy.NatureMethods14,331–332(2017). 31.Punjani,A.,Rubinstein,J.L.,Fleet,D.J.&Brubaker,M.A.cryoSPARC:algorithms for rapid unsupervised cryo-EM structuredetermination.NatureMethods14,290–296(2017). 32.Punjani,A.,Zhang,H.&Fleet,D.J.Non-uniform refinement:Adaptiveregularization improves single particle cryo-EMreconstruction.bioRxiv2019.12.15.877092(2019).doi:10.1101 / 2019.12.15.877092 33.Wang,W.et al.The Structure of an Open Form of an E.coliMechanosensitive Channel at 3.45 A Resolution.Science321,1179–1183(2008). 34.Jurcik,A.et al.CAVER Analyst 2.0:analysis and visualization ofchannels and tunnels in protein structures and moleculardynamicstrajectories.Bioinformatics(Oxford,England)34,3586–3588(2018). 35.Smart,O.S.,Goodfellow,J.M.&Wallace,B.A.The pore dimensions ofgramicidin A.Biophysical journal65,2455–60(1993).36.Kefauver,J.M.,Ward,A.B.&Patapoutian,A.Discoveries in structure and physiology of mechanicallyactivated ion channels.Nature 587,567–576(2020). 37.Hurst AC,Petrov E,Kloda A,Nguyen T,Hool L,Martinac B.MscS,thebacterial mechanosensitive channel of smallconductance.Int J Biochem CellBiol.2008;40(4):581-585. 38.Malcolm,H.R.and Maurer,J.A.(2012),The Mechanosensitive Channel ofSmall Conductance(MscS)Superfamily:Not JustMechanosensitive ChannelsAnymore.ChemBioChem,13:2037-2043.

Claims

1. An application of an angstrom pore system in detecting charged molecules, characterized in that: The angstrom system comprises an angstrom pore, an insulating film, a first medium and a second medium; the angstrom pore is embedded in the insulating film, the insulating film separates the first medium from the second medium, the angstrom pore provides a channel connecting the first medium and the second medium, and after a driving force is applied between the first medium and the second medium, the charged molecules located in the first medium interact with the angstrom pore; the angstrom pore is an MscS angstrom pore, and the angstrom pore has a radially symmetrical and cylindrical heptamer structure, and the heptamer structure comprises 7 side openings and 1 bottom opening.

2. The use according to claim 1, characterized in that The charge property and / or pore size of the opening is adjustable; the adjustment method of the opening optionally includes subjecting the insulating membrane to mechanical force stimulation and / or changing the physical state of the insulating membrane, and the mechanical force stimulation optionally includes one or more of the change in osmotic pressure difference of the medium on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by microneedles, and stimulation of the insulating membrane by negative air pressure.

3. The use according to claim 1, characterized in that The aperture of the opening can be adjusted in the following ways: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.

4. The use according to claim 1, characterized in that The emphipores are derived from bacilli, and may optionally include one or more of Pseudomonas aeruginosa, Escherichia coli, Thermoanaerobacterium Tengchongensis, and Helicobacter pylori.

5. The use according to claim 1, characterized in that The angstrom pore is a MscS variant, which may optionally include a side pore volume variant and / or a side pore charge variant.

6. The use according to claim 1, characterized in that The charged molecules include one or more of nucleotides, amino acids, peptides, and drug molecules.

7. The use according to claim 1, characterized in that The angstrom pore is a PaMscS variant, optionally including one or more of the following variants: 130A, 130H, 180R, 271I, 130S and 130P.

8. A biological angstrom pore system, characterized in that: The biological angstrom system comprises an angstrom pore, an insulating film, a first medium and a second medium, wherein the angstrom pore is embedded in the insulating film, the insulating film separates the first medium from the second medium, and the angstrom pore provides a channel connecting the first medium and the second medium; The angstrom pore is a variant angstrom pore of MscS, which has a radially symmetrical and cylindrical heptameric structure, wherein the heptameric structure comprises 7 side openings and 1 bottom opening. The angstrom pore is optionally a side pore volume variant and / or a side pore charge variant of MscS.

9. The biological angstrom system according to claim 8, characterized in that The emphipores are derived from bacilli, and may optionally include one or more of Pseudomonas aeruginosa, Escherichia coli, Thermoanaerobacterium Tengchongensis, and Helicobacter pylori.

10. The biological angstrom system according to claim 8, characterized in that: The angstrom pore is a PaMscS variant, optionally including one or more of the following variants: 130A, 130H, 180R, 271I, 130S and 130P.

11. The biological angstrom system according to claim 8, characterized in that The charge property and / or pore size of the opening is adjustable; the adjustment method of the opening optionally includes subjecting the insulating membrane to mechanical force stimulation and / or changing the physical state of the insulating membrane, and the mechanical force stimulation optionally includes one or more of the change in osmotic pressure difference of the medium on both sides of the insulating membrane, direct physical stimulation of the insulating membrane by microneedles, and stimulation of the insulating membrane by negative air pressure.

12. The biological angstrom system according to claim 8, characterized in that The aperture of the opening can be adjusted in the following ways: (1) Selection of the types of the first medium and the second medium; and / or (2) The osmotic pressure difference between the first medium and the second medium.

13. Use of the biological angstrom pore system according to any one of claims 8 to 12 in detecting charged molecules, characterized in that: The charged molecules include one or more of nucleotides, amino acids, peptides, and drug molecules.